GenFleet Therapeutics (Shanghai) Inc.
勁方醫藥科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2595)

VOLUNTARY ANNOUNCEMENT
World's First Registrational Phase III Study for Oral KRAS G12D Inhibitor in NSCLC Advances, as First Patient Dosed in GFH375's Second Registrational Study

This announcement is made by GenFleet Therapeutics (Shanghai) Inc. (the "**Company**" or "**GenFleet**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce GFH375, an oral KRAS G12D inhibitor, has advanced into a multicenter, open-label, randomized controlled registrational phase III study ("**Kylin-Flight 01**") in China evaluating monotherapy efficacy and safety versus docetaxel in patients with KRAS G12D-mutant locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) who have failed standard-of-care therapy. The trial will be conducted across more than 40 clinical sites nationwide, with the first patient recently dosed at Nanjing Drum Tower Hospital (南京鼓樓醫院). Previously, GFH375 entered the world's first registrational phase III study ("**Kylin-Wings 01**") of an oral KRAS G12D inhibitor in pancreatic cancer last year. This year, GFH375 received China's first two Breakthrough Therapy Designations (BTD) in China for monotherapy treating KRAS G12D-mutant NSCLC and pancreatic cancer respectively.

Currently, no targeted therapy is approved globally for patients with KRAS G12D mutations, and first-line standard of care for this patient population adopts the treatment paradigm in oncogene-negative NSCLC. Yet prior research has shown that KRAS-mutant NSCLC patients exhibit relatively low sensitivity to chemotherapy and tend to acquire resistance more rapidly driven by epigenetic mechanisms. Compounding the challenge, PD-L1 expression in KRAS G12D patients is typically low, leaving this subset with poorer response rates to PD-1/L1 inhibitor monotherapy among patients harboring various KRAS mutation subtypes. In the second-line setting and beyond, objective response rates and overall survival benefits remain modest - with regimens including immunotherapy, or chemotherapy with or without anti-angiogenic agents. GFH375 has emerged

as a potential best-in-class KRAS G12D inhibitor in global landscape and its latest monotherapy data for late-line NSCLC treatment will be delivered in an oral presentation at this year's World Conference on Lung Cancer (WCLC).

“Targeted therapy for lung cancer has advanced rapidly over the past two decades. However, substantial unmet medical needs persist for KRAS G12D-mutant NSCLC, as no targeted therapies have been approved globally to date. GFH375 sits at the global forefront of clinical development for this indication. Encouraging preliminary data shared via oral presentations at last year’s American Society of Clinical Oncology (ASCO) and WCLC annual meetings have strengthened our confidence in launching this registrational trial. Factoring in product profiles, trial progress and clinical imperatives, we have designed the most feasible and efficient study plan, with the expectation to reshape the treatment landscape for KRAS G12D-mutant NSCLC.” stated Professor Shun Lu (陆舜) from Shanghai Chest Hospital (上海市胸科醫院).

"We are delighted to announce the initiation of the second registrational phase III study of GFH375. Since its clinical development in 2024, GFH375 has demonstrated promising efficacy in NSCLC, with NSCLC treatment data consecutively selected for oral presentations or late-breaking abstracts (LBA) at major international academic events. Bolstered by robust phase I/II monotherapy results, we are confident in the rapid advancement of NSCLC trials against the global NSCLC treatment landscape. Concurrently, the registrational phase III study in pancreatic cancer, initiated last year, is progressing on track. We look forward to bringing new, transformative targeted treatment options to patients through monotherapy and combination regimens of this KRAS G12D inhibitor." stated Yu Wang, M.D., Ph.D., Chief Medical Officer of GenFleet.

About GFH375/VS-7375

GFH375 is an orally active, potent, highly selective small-molecule KRAS G12D (ON/OFF) inhibitor designed to bind to the protein of KRAS G12D non-covalently, thereby disrupting the activation of downstream pathways and effectively inhibiting tumor cell proliferation. Preclinical studies demonstrated dose-dependent inhibition in models bearing KRAS G12D mutation; GFH375 also demonstrated low off-target risk in kinase selectivity and safety target assays. GenFleet entered into a discovery and development collaboration with Verastem Oncology (“**Verastem**”) to advance three novel oncology discovery programs related to RAS/MAPK pathway-driven cancers. The collaboration provides Verastem with an exclusive option to obtain a license for each of the three compounds in the collaboration after the successful completion of pre-determined milestones in a Phase I trial. Verastem selected GFH375/VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, as its lead program from the collaboration in December 2023 and the license for GFH375 that was exercised in January 2025 is the first one from this collaboration. The licenses would give Verastem development and commercialization rights outside of China while GenFleet would retain rights inside of China.

Forward-looking Statements

Specific information in this announcement may contain or constitute forward-looking words that are not historical facts. They can be identified by using forward-looking terminology, such as “predict”, “believe”, “plan”, “forecast”, “expect”, “will”, “may”, “should” and other words of similar meanings. Based on the management’s current beliefs, plans, estimates and expectations of the Company’s operation and market trends subject to changes beyond control, the forward-looking terminology reflects the Company’s beliefs, plans, estimates and expectations of future development. Actual outcome in the future may differ significantly from forward-looking words owing to market, policy, and R&D uncertainties, among others. Subject to the above-mentioned uncertainties, the Company makes no expressed or implied guarantee as to the accuracy, completeness or feasibility of this presentation, and you are cautioned not to solely rely on such forward-looking words. Neither the company nor any of its directors, officers, employees, shareholders, agents, related parties, consultants or representatives will be liable to you or any other person for consequences resulting from using this presentation. Investors are advised to exercise due diligence with reference to the company’s official disclosures for decision-making.

GLOSSARY OF TECHNICAL TERMS

“ASCO”	American Society of Clinical Oncology
“BTD”	Breakthrough Therapy Designation
“KRAS”	Kirsten RAS, a member of the RAS family of proteins
“LBA”	Late-breaking Abstract
“MAPK”	mitogen-activated protein kinase, a family of proteins involved in transmitting signals from cell surface receptors to the nucleus
“NSCLC”	non-small cell lung cancer
“PD-1”	Programmed Death Receptor 1 is a vital immunosuppressive molecule. It modulates the immune system and promotes self-tolerance by downregulating the immune system’s response to human cells and curbing inflammatory activity in T cells
“PD-L1”	Programmed Death Ligand 1 is a type I transmembrane glycoprotein present in the human body. Intact PD-L1 consists of an extracellular domain, a hydrophobic transmembrane domain and an intracellular domain. Its extracellular IgV-like and IgC-like domains serve as critical regions for binding to PD-1

"RAS"	ras sarcoma, a family of proteins that are critical regulators of cellular signaling pathways; it primarily includes HRAS, KRAS, and NRAS
"WCLC"	World Congress on Lung Cancer

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market GFH375 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, August 10, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive directors.